Phase I Study of PLX4032: Proof of Concept for V600E BRAF Mutation as a Therapeutic Target in Human Cancer Flaherty K et al. American Society of Clinical.

Slides:

Advertisements

Similar presentations

Accenture Life Sciences Rethink Reshape Restructure… for better patient outcomes CDISC Journey in Lymphoma using Cheson 2007 Kevin Lee CDISC NJ meeting.

Advertisements

Ulrik Lassen MD, PH.D Phase 1 Unit

Paz-Ares LG et al. Proc ASCO 2011;Abstract CRA7510.

The 70-Gene Profile and Chemotherapy Benefit in 1,600 Breast Cancer Patients Bender RA et al. ASCO 2009; Abstract 512. (Oral Presentation)

Can We Define Tumors That Will Respond to PARP Inhibitors? A Phase II Correlative Study of Olaparib in Advanced Serous Ovarian Cancer and Triple-Negative.

Cases on 1st line use of Ipilimumab in BRAF+ patients, sequencing of therapies Erika Richtig.

BRF Begin with BRAF Searching for a target in metastatic melanoma?

October 23, 2014 John C. Lin, M.D. Ph.D. Vice President, Experimental Medicine Rational Combination of Immunotherapies in Preclinical Cancer Models.

Selezione dei pazienti affetti da melanoma Vanna Chiarion Sileni Melanoma and Skin Cancer Unit IOV-IRCCS, Padova.

Survival, response duration, and activity by BRAF mutation (MT) status of nivolumab (NIVO, anti-PD-1, BMS , ONO-4538) and ipilimumab (IPI) concurrent.

Phase 1/2 Study of GSK , a Selective Inhibitor of Oncogenic Mutant BRAF Kinase in Patients with Metastatic Melanoma and Other Solid Tumors Kefford.

Improved Survival with Vemurafenib in Melanoma with BRAF V600E Mutation 1 Phase III Randomized, Open-Label, Multicenter Trial (BRIM3) Comparing BRAF Inhibitor.

SYSTEMIC THERAPY FOR UNRESECTABLE STAGE III OR METASTATIC CUTANEOUS MELANOMA Sarkheil Mehdi Hematologist- oncologist.

New Developments in Cancer Treatment Dulcinea Quintana, MD.

Efficacy and Safety of Single Agent Sunitinib in Treating Advanced Hepatocelluar Carcinoma Patients After Sorafenib Failure: A Prospective, Open-Label,

Cabozantinib (XL184) in Metastatic Castration-Resistant Prostate Cancer (mCRPC): Results from a Phase II Randomized Discontinuation Trial Hussain M et.

About these slides SPEC – Short Presentation in Emerging Concepts Provided by the CAP as an aid to pathologists to facilitate discussion on the topic.

Weekly MLN9708, an Investigational Oral Proteasome Inhibitor, in Relapsed/Refractory Multiple Myeloma: Results from a Phase I Study After Full Enrollment.

Renal cell cancer: Integrating novel agents into a therapeutic algorithm Robert Dreicer, M.D., FACP Chairman Department of Solid Tumor Oncology Taussig.

Phase III Trial of Pazopanib in Locally Advanced and/or Metastatic Renal Cell Carcinoma Sternberg CN et al. ASCO 2009; Abstract (Oral Presentation)

Final Results of a Phase 1 Study of Idelalisib (GS-1101), a Selective Inhibitor of Phosphatidylinositol 3-Kinase p110 Delta (PI3K), in Patients with Relapsed.

Activity and Tolerability of Afatinib (BIBW 2992) and Cetuximab in NSCLC Patients with Acquired Resistance to Erlotinib or Gefitinib Janjigian YY et al.

Ibrutinib in Combination with Bendamustine and Rituximab Is Active and Tolerable in Patients with Relapsed/Refractory CLL/SLL: Final Results of a Phase.

Bang Y et al. Proc ASCO 2010;Abstract 3.

Lenalidomide Is Safe and Active in Waldenstrom Macroglobulinemia (WM) 1 Updated Results from a Multicenter, Open-Label, Dose-Escalation Phase 1b/2 Study.

Byrd JC et al. Proc ASCO 2011;Abstract 6508.

Stereotactic Ablative Body Radiotherapy for Non small cell lung cancer

Final Efficacy Results from OAM4558g, a Randomized Phase II Study Evaluating MetMAb or Placebo in Combination with Erlotinib in Advanced NSCLC Spigel DR.

Cortés J et al. ASCO 2009; Abstract (Poster Discussion)

Audeh MW et al. ASCO 2009; Abstract (Clinical Science Symposium)

Raafat R. Abdel-Malek, MD, FRCR Ass. Prof Clinical Oncology Cairo University, Egypt Efficacy & Toxicity of Sunitinib in mRCC patients in Egypt.

A Phase 2 Study with a Daily Regimen of the Oral mTOR Inhibitor RAD001 (Everolimus) in Patients with Metastatic Clear Cell Renal Cell Cancer Amato RJ et.

CD-1 Second-line Chemotherapy for Hormone Refractory Prostate Cancer Disease Background Nicholas J. Vogelzang, MD Director Nevada Cancer Institute CD-1.

Cabozantinib (XL184) in metastatic castration- resistant prostate cancer (mCRPC): Results from a phase II randomized discontinuation.

Phase II Trial of Ipilimumab Monotherapy in Melanoma Patients with Brain Metastases Lawrence DP et al. Proc ASCO 2010;Abstract 8523.

In my clinical practice I use FDG-PET for the following 1- Staging 2- Therapeutic monitoring 3- Staging and therapeutic monitoring 4- I do not use FDG-PET;

Clinicopathologic Features of EML4-ALK Mutant Lung Cancer Shaw AT et al. ASCO 2009; Abstract (Poster)

Results of a Phase 2, Multicenter, Single-Arm Study of Eribulin Mesylate as First-Line Therapy for Locally Recurrent or Metastatic HER2-Negative Breast.

Prof. Jae Heon, Jeong/R2 Cheol Hyun, Lee J of Clinical oncology, Vol 31 Number 4, Feb.1, 2013.

CCO Independent Conference Coverage* of the 2016 ASCO Annual Meeting, June 3-7, 2016 Phase II MONARCH 1: CDK4/6 Inhibitor Abemaciclib in HR+/HER2- MBC.

CCO Independent Conference Coverage

CCO Independent Conference Highlights

CCO Independent Conference Coverage

ECHO-204: Preliminary Results of Phase I/II Trial of Epacadostat + Nivolumab in Advanced Solid Tumors CCO Independent Conference Highlights* of the 2017.

CCO Independent Conference Highlights

Reeder CB et al. ASCO 2009; Abstract (Poster)

Gajria D et al. Proc SABCS 2010;Abstract P

Phase I/II Study of Lorlatinib in Advanced ALK+ or ROS1+ NSCLC

SIRveNIB: Randomized Phase III Trial of Selective Internal Radiation Therapy vs Sorafenib in Locally Advanced HCC CCO Independent Conference Highlights*

Combined Inhibition of PD-L1, MEK, and BRAF Active in Advanced Melanoma CCO Independent Conference Highlights of the 2015 ASCO Annual Meeting* May 29 -

KEYNOTE-012: Durable Efficacy With Pembrolizumab in PD-L1–Positive Gastric Cancer CCO Independent Conference Highlights of the 2015 ASCO Annual Meeting*

Dose-escalation patient response.

Program Goals. Implementing the Updated American Thyroid Association Guidelines and Recommendations for RAI-R DTC.

Proof-of-concept clinical studies validating AZD9291 as a mutant-selective EGFR kinase T790M inhibitor. Proof-of-concept clinical studies validating AZD9291.

Krop I et al. SABCS 2009;Abstract 5090.

Treating mRCC After Initial Antiangiogenic Therapy:

Program Goals. Implementing the Updated American Thyroid Association Guidelines and Recommendations for RAI-R DTC.

Meta-analysis of randomised phase III clinical trials with ALK inhibitors in non-small cell lung cancer (NSCLC) showing similar benefit in male patients.

Waterfall plot of the best per cent change from baseline in SLD of target lesions in 33 patients. Waterfall plot of the best per cent change from baseline.

Clinical responses in patients.

Clinical courses of patients.

Efficacy of BSI-201, a PARP Inhibitor, in Combination with Gemcitabine/Carboplatin (GC) in Triple Negative Metastatic Breast Cancer (mTNBC): Results.

Clinical response to anti-ERBB3 mAb therapy in a patient with an advanced NRG1-rearranged non–small cell lung cancer. Clinical response to anti-ERBB3 mAb.

A 63-year-old female with lung adenocarcinoma treated with nivolumab, who experienced pseudoprogression. A 63-year-old female with lung adenocarcinoma.

Representative patient responses to ulixertinib.

The best response for target lesions per patient for patients with target lesions assessed at baseline and at least 1 follow-up. The best response for.

Serial CT scan images from patient with a partial response.

Survival, subsequent therapies, and response.

Presentation transcript:

Phase I Study of PLX4032: Proof of Concept for V600E BRAF Mutation as a Therapeutic Target in Human Cancer Flaherty K et al. American Society of Clinical Oncology 2009; Abstract (Clinical Science Symposium Presentation)

Source: Flaherty K et al. ASCO 2009; Abstract Introduction V600E BRAF kinase activating mutation –Point mutation that constitutively activates map-kinase pathway –Observed in 6-8% of all cancers, including melanoma (60%) colorectal cancer (10%), anaplastic and papillary thyroid carcinomas, low-grade serous ovarian carcinomas Phase I, sequential dose-escalation study of PLX4032 (oral agent — the most selective BRAF inhibitor to have entered clinical development — N = 55: 49 melanoma, 3 thyroid, 1 rectal, 1 ovarian, 1 germ cell)

Patients (n = 15)* (RECIST cutoff for PR, 30%) Source: With permission from Flaherty K et al. ASCO 2009; Abstract Results Patients with BRAF V600E Melanoma Treated with PLX4032 > 240 mg BID * One patient with M1c had 55% reduction in target lesions, but PD in non-target lesions; died before end C2 (not included above) % change from baseline (sum of lesion size)

Source: With permission from Flaherty K et al. ASCO 2009; Abstract Results Patient with BRAF V600E Melanoma PET Scan at Baseline and Day +15 Treatment at 320 mg BID A patient with response in extensive “intransit” metastases on the leg and more distant skin and lymph node sites

Source: Flaherty K et al. ASCO 2009; Abstract Summary and Conclusions Nearly all AEs were mild and transient, mostly rash, fatigue, photosensitivity but also cutaneous squamous cell cancer following chronic dosing (n = 6) Responses to PLX4032 with V600E+ melanoma –9 PRs in 15 patients –Regression of liver, lung and bone metastases –Symptom improvement in many patients –Premature to define PFS, but it appears to be ~6 months, with many patients still on therapy –No evidence of tumor regression in 5 patients with V600E- negative disease 3 patients with V600E+ papillary thyroid carcinoma: 1 PR, 2 SD Additional trials planned in melanoma, colorectal cancer and papillary thyroid carcinoma